SOLICITATION NOTICE
65 -- Pharmaceutical Distribution in South Africa
- Notice Date
- 7/12/2004
- Notice Type
- Solicitation Notice
- NAICS
- 424210
— Drugs and Druggists' Sundries Merchant Wholesalers
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, MD, 20817
- ZIP Code
- 20817
- Solicitation Number
- NIAID-OCR-04-70
- Point of Contact
- Terrie Nestor, Contract Specialist, Phone 301-402-6790, Fax 301-480-0689,
- E-Mail Address
-
tnestor@niaid.nih.gov
- Description
- The National Institute of Allergy and Infectious Diseases (NIAID), Acquisitions Management and Operations Branch (AMOB) has an unrestricted requirement for pharmaceutical distribution within South Africa. NIAID intends to award a one year contract with the option for four additional years beginning on or before September 30, 2004. The resulting contract will also contain the provision at FAR 52.217-8. The contractor will be responsible for providing the antiretroviral drugs (ARV) identified below to the South African National Defense Force (SANDF) pharmacy depot upon receipt of individual delivery orders. All ARVs are brand name specific, identified by a manufacturer's commercial item description, and conform to the manufacturer's commercial specifications. Offerors must be licensed with the Medicines Control Council or indicate that they will use approved distribution channels. Offerors will be evaluated on past performance, storage space and storage conditions, and infrastructure to fulfill the order placement, delivery, and invoice requirements as outlined in the Statement of Work. The required ARVs are as follows: Didanosine (Videx?, Videx EC?, Bristol-Myers Squibb) - various dosages and formulations; Efavirenz (Stocrin?, MSD) - 200mg capsules, 50mg capsules; Lamivudine (Epivir? or 3TC?, Glaxo Smith Kline) - 150mg tablet or oral solution; Lopinavir/Ritonavir (Kaletra?, Abbott) - 133mg/33mg capsules, oral liquid formulation; Nevirapine (Viramune?, Boehringer-Ingelheim) - 200mg capsules, 50mg/5mL suspension; Stavudine (Zerit?, Bristol-Myers Squibb) - 40mg, 30mg, 20mg capsules and 1mg/mL oral solution; Zidovudine (Retrovir?, Glaxo Smith Kline) - 300mg tablets, 100mg capsules, and oral syrup. (Question Marks indicate trademark symbols.) Substitutions or changes to the identified ARVs may be required over the life of the contract. The solicitation may result in multiple awards. The NIAID intends to award a commercial item, FFP/EPA contract. The solicitation will be available for download on or around July 16, 2004 at www.fedbizopps.gov. Hard copies of the solicitation will not be distributed. Please refer all questions in writing to Terrie Nestor at tnestor@niaid.nih.gov.
- Place of Performance
- Address: TBD
- Record
- SN00618971-W 20040714/040712211821 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |